Alzamend Neuro, Inc. (ALZN)
NASDAQ: ALZN · Real-Time Price · USD
2.250
+0.100 (4.65%)
At close: Dec 5, 2025, 4:00 PM EST
2.239
-0.011 (-0.51%)
After-hours: Dec 5, 2025, 7:20 PM EST
Alzamend Neuro Employees
As of April 30, 2025, Alzamend Neuro had 7 total employees, including 4 full-time and 3 part-time employees. The number of employees did not change compared to the previous year.
Employees
7
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$976,194
Market Cap
8.55M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ALZN News
- 16 days ago - Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 "Lithium in Brain" Study Conducted at Massachusetts General Hospital - PRNewsWire
- 4 months ago - Alzamend Neuro to Present at the 2025 Military Health System Research Symposium - GlobeNewsWire
- 4 months ago - Alzamend Neuro Reports Annual 2025 Financial Results and Provides Update on Clinical Programs - GlobeNewsWire
- 6 months ago - Alzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of Schedule - GlobeNewsWire
- 6 months ago - Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital - GlobeNewsWire
- 7 months ago - Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital - GlobeNewsWire
- 7 months ago - Alzamend Neuro Initiates First Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital - GlobeNewsWire
- 7 months ago - Alzamend Neuro Announces Reverse Stock Split - GlobeNewsWire